论文部分内容阅读
目的研究无创正压通气(BIPAP)治疗慢性阻塞性肺疾病(COPD)并发慢性II型呼吸衰竭的临床疗效。方法 76例COPD并发慢性II型呼吸衰竭的患者,住院期间均应用BIPAP呼吸机治疗稳定后出院,出院后在患者知情同意下,将患者分为A组和B组,A组36例患者,在药物治疗基础上继续给予BIPAP呼吸机治疗,每天应用呼吸机>6 h,B组40例患者应用药物治疗;观察半年,比较两组血液pH值、PaO2、PaCO2、呼吸频率以及心率及肺功能(FEV1)。结果 A组治疗后血液pH值显著高于B组,PaO2显著高于B组,PaCO2显著低于B组,两组比较差异具有统计学意义(P<0.05);A组治疗后呼吸频率和心率显著低于对照组,两组比较差异具有统计学意义(P<0.05);A组FEV1值高于B组,两组比较差异无统计学意义(P>0.05)。结论 BIPAP呼吸机治疗稳定期COPD并慢性Ⅱ型呼吸衰竭患者具有较好的疗效,能显著改善患者的血气指标。
Objective To investigate the clinical efficacy of noninvasive positive pressure ventilation (BIPAP) in the treatment of chronic obstructive pulmonary disease (COPD) complicated with chronic type II respiratory failure. Methods Totally 76 patients with COPD complicated with chronic type II respiratory failure were treated with BIPAP ventilator during stable hospital stay. After discharge, patients were divided into group A and group B with informed consent. A group of 36 patients On the basis of drug treatment, BIPAP ventilator was continued to be treated. Ventilator was applied for> 6 h every day, and 40 patients in group B were treated with drugs. After six months, blood pH, PaO2, PaCO2, respiration rate, heart rate and lung function FEV1). Results After treatment, the blood pH of group A was significantly higher than that of group B, PaO2 was significantly higher than that of group B, PaCO2 was significantly lower than that of group B, the difference was statistically significant (P <0.05); The respiratory rate and heart rate (P <0.05). The FEV1 in group A was higher than that in group B, and there was no significant difference between the two groups (P> 0.05). Conclusion BIPAP ventilator has good curative effect in patients with stable COPD and chronic type Ⅱ respiratory failure, and can significantly improve the blood gas index of patients.